Treatment of Acquired von Willebrand Syndrome in Patients with Alloantibodies to vWF or Refractory to Standard Therapy
Acquired von Willebrand syndrome poses a particular management challenge when patients develop alloantibodies to von Willebrand factor or when standard therapeutic measures have failed to achieve adequate haemostatic control. A targeted pharmacological approach is required in these cases.
Clinical scenario: Patients with acquired von Willebrand syndrome who have developed alloantibodies to von Willebrand factor, or who remain refractory to standard therapy, require an alternative treatment strategy. This protocol addresses that specific situation.
Management in this setting involves a recombinant activated coagulation factor given intravenously in a defined dosing cycle. This agent is considered valuable and highly effective in the population described above.
The complete dosing schedule, cycle length, administration guidance, and monitoring criteria are provided in the full protocol — accessible below.
References
DOI: 10.5603/ahp.107038
- In patients who have developed alloantibodies to vWF, recombinant activated factor VIIA (rVIIa) is a valuable and highly effective drug.
- It is usually administered at a dose of 90 μg/kg (range, 40–150 μg/kg), in a cycle of approximately three doses.
- The use of rVIIa should be considered especially in patients who are refractory to standard therapy.
View source ↗